Ketamine offers promising new therapeutic options for difficult-to-treat depression. The efficacy of treatment response, including ketamine, has been intricately linked to EEG measures of vigilance. This research investigated the interplay between intravenous ketamine and alterations in brain arousal, quantified through EEG vigilance assessments in two distinct cohorts of depressed patients (original dataset: n = 24; testing dataset: n = 24). Clinical response was defined as a decrease from baseline of >33% on the Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after infusion. EEG recordings were obtained pre-, start-, end- and 24 h post- infusion, and the resting EEG was automatically scored using the Vigilance Algorithm Leipzig (VIGALL). Relative to placebo (sodium chloride 0.9%), ketamine increased the amount of low-vigilance stage B1 at end-infusion. This increase in B1 was positively related to serum concentrations of ketamine, but not to norketamine, and was independent of clinical response. In contrast, treatment responders showed a distinct EEG pattern characterized by a decrease in high-vigilance stage A1 and an increase in low-vigilance B2/3, regardless of whether placebo or ketamine had been given. Furthermore, pretreatment EEG differed between responders and non-responders with responders showing a higher percentage of stage A1 (53% vs. 21%). The logistic regression fitted on the percent of A1 stages was able to predict treatment outcomes in the testing dataset with an area under the ROC curve of 0.7. Ketamine affects EEG vigilance in a distinct pattern observed only in responders. Consequently, the percentage of pretreatment stage A1 shows significant potential as a predictive biomarker of treatment response.Clinical Trials Registration: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000952-17/CZ Registration number: EudraCT Number: 2013-000952-17.

Center for Cognitive and Brain Sciences University of Macau Taipa Macau SAR China

Charles University 3rd Faculty of Medicine Prague Czech Republic

Epilepsy Clinic University Hospital Rigshospitalet Copenhagen Denmark

Hospital for Psychiatry Psychotherapy and Psychosomatic

National Institute of Mental Health Klecany Czech Republic

Neurobiology Research Unit University Hospital Rigshospitalet Copenhagen Denmark

University Zurich Zurich Switzerland

000      

00000naa a2200000 a 4500

001      

bmc24007502

003      

CZ-PrNML

005      

20240423160021.0

007      

ta

008      

240412s2024 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1038/s41398-024-02761-x $2 doi

035    __

$a (PubMed)38272875

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Ip, Cheng-Teng $u Center for Cognitive and Brain Sciences, University of Macau, Taipa, Macau SAR, China $u Neurobiology Research Unit, University Hospital Rigshospitalet, Copenhagen, Denmark

245    10

$a EEG-vigilance regulation is associated with and predicts ketamine response in major depressive disorder / $c CT. Ip, M. de Bardeci, G. Kronenberg, LH. Pinborg, E. Seifritz, M. Brunovsky, S. Olbrich

520    9_

$a Ketamine offers promising new therapeutic options for difficult-to-treat depression. The efficacy of treatment response, including ketamine, has been intricately linked to EEG measures of vigilance. This research investigated the interplay between intravenous ketamine and alterations in brain arousal, quantified through EEG vigilance assessments in two distinct cohorts of depressed patients (original dataset: n = 24; testing dataset: n = 24). Clinical response was defined as a decrease from baseline of >33% on the Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after infusion. EEG recordings were obtained pre-, start-, end- and 24 h post- infusion, and the resting EEG was automatically scored using the Vigilance Algorithm Leipzig (VIGALL). Relative to placebo (sodium chloride 0.9%), ketamine increased the amount of low-vigilance stage B1 at end-infusion. This increase in B1 was positively related to serum concentrations of ketamine, but not to norketamine, and was independent of clinical response. In contrast, treatment responders showed a distinct EEG pattern characterized by a decrease in high-vigilance stage A1 and an increase in low-vigilance B2/3, regardless of whether placebo or ketamine had been given. Furthermore, pretreatment EEG differed between responders and non-responders with responders showing a higher percentage of stage A1 (53% vs. 21%). The logistic regression fitted on the percent of A1 stages was able to predict treatment outcomes in the testing dataset with an area under the ROC curve of 0.7. Ketamine affects EEG vigilance in a distinct pattern observed only in responders. Consequently, the percentage of pretreatment stage A1 shows significant potential as a predictive biomarker of treatment response.Clinical Trials Registration: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000952-17/CZ Registration number: EudraCT Number: 2013-000952-17.

650    _2

$a lidé $7 D006801

650    _2

$a mozek $7 D001921

650    12

$a depresivní porucha unipolární $x farmakoterapie $7 D003865

650    _2

$a elektroencefalografie $7 D004569

650    12

$a ketamin $x farmakologie $x terapeutické užití $7 D007649

650    _2

$a bdění $7 D014851

655    _2

$a časopisecké články $7 D016428

700    1_

$a de Bardeci, Mateo $u Hospital for Psychiatry, Psychotherapy and Psychosomatic; University Zurich, Zurich, Switzerland

700    1_

$a Kronenberg, Golo $u Hospital for Psychiatry, Psychotherapy and Psychosomatic; University Zurich, Zurich, Switzerland

700    1_

$a Pinborg, Lars Hageman $u Neurobiology Research Unit, University Hospital Rigshospitalet, Copenhagen, Denmark $u Epilepsy Clinic, University Hospital Rigshospitalet, Copenhagen, Denmark

700    1_

$a Seifritz, Erich $u Hospital for Psychiatry, Psychotherapy and Psychosomatic; University Zurich, Zurich, Switzerland

700    1_

$a Brunovsky, Martin $u National Institute of Mental Health, Klecany, Czech Republic $u Charles University, Third Faculty of Medicine, Prague, Czech Republic $1 https://orcid.org/0000000224830848 $7 xx0070660

700    1_

$a Olbrich, Sebastian $u Hospital for Psychiatry, Psychotherapy and Psychosomatic; University Zurich, Zurich, Switzerland. Sebastian.olbrich@pukzh.ch $1 https://orcid.org/0000000155574878

773    0_

$w MED00177206 $t Translational psychiatry $x 2158-3188 $g Roč. 14, č. 1 (2024), s. 64

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38272875 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423160018 $b ABA008

999    __

$a ok $b bmc $g 2081479 $s 1217269

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 14 $c 1 $d 64 $e 20240126 $i 2158-3188 $m Translational psychiatry $n Transl Psychiatry $x MED00177206

GRA    __

$a R279-2018-1145 $p Lundbeckfonden (Lundbeck Foundation)

GRA    __

$a R279-2018-1145 $p Lundbeckfonden (Lundbeck Foundation)

GRA    __

$a 19-0219 $p Augustinus Fonden (Augustinus Foundation)

GRA    __

$a SRG2023-00040-ICI $p Universidade de Macau (University of Macau)

LZP    __

$a Pubmed-20240412